Skip to content
‹ Back to IndustriesSciences

Listen: Space, The VR Frontier with Tanya Gupta of NASA

The retirement of NASA's Space Shuttle program in 2010 led to a lull in space exploration plans, until private companies like SpaceX revitalized the industry. Tanya Gupta, a VR intern, discusses how VR technology is contributing to advancements in aerospace engineering. She emphasizes the collaborative efforts between NASA and private companies fostering innovation.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Featured Podcast
Share
Listen: Space, The VR Frontier with Tanya Gupta of NASA

Key takeaways

01

Private companies like SpaceX and Blue Origin have played a crucial role in revitalizing space exploration.

02

Advancements in VR and AR technology are accelerating innovation in aerospace engineering.

03

Tanya Gupta is using VR to enhance and simplify processes at NASA's Kennedy Space Center.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The future of space exploration looked bleak after 2010 when NASA’s Space Shuttle program was officially retired. Beyond satellites and research conducted from the ISS, there weren’t many plans to travel the stars. That is, until private companies such as SpaceX, Blue Origin, Orbital ATK, and others fundamentally changed the way the industry operated, pushing the limits of who could take the next steps beyond Earth. Enter Tanya Gupta, a VR intern at NASA’s Kennedy Space Center.

Because of these thriving government and private partnerships for space travel, technology in the space is flourishing, allowing for upgrades in AR and VR to take hold and grow exponentially. Tanya joined us on this Science episode of Wildfire to give us insight on how technology like VR is simplifying and speeding up the process for innovation in aerospace engineering, the collaborative power of NASA, and why being a creative in the STEM space was so important for her (pun intended). She also sheds a little light on her fabulous twitter name, Space Barbie.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Merck has invested more than €300 million in a new bioprocessing production center in Daejeon, South Korea. It is the largest life science investment Merck has made in the region to date. The 44,500-square-meter facility makes cell culture media, process liquids and sterile sampling products to support biologics manufacturing from development through commercial supply.

  • 01A single Asia-Pacific site now supplies both small custom pre-GMP media and commercial-scale media, so a regional biologics program could scale without switching to a source outside the region.
  • 02Daejeon supplies cell culture media, process liquids, ready-to-use cleaning-in-place solutions and sterile sampling products.
  • 03The useful supplier question has moved past whether Merck has an Asia-Pacific plant: ask which product lines ship from Daejeon and what batch traceability data customers can see.

Nov 3, 2026

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox projects the quantum cascade laser market to grow 8% to 12% a year through 2035, linking the outlook to faster adoption of mid-infrared spectroscopy in process control, environmental monitoring and pharmaceutical QA. It says QCLs win on high spectral brightness and room-temperature operation in compact form factors, and that the installed base of analytical instruments is growing.

  • 01Roughly one in three quantum cascade lasers shipped in 2030 is projected to replace equipment already in service, so maintenance calendars will set a growing share of demand.
  • 02For a plant or QA lab running QCL-based analyzers, the useful question is which laser maker sits inside each instrument and whether a second source exists.
  • 03Analyzers bought on a three-to-five-year cycle in 2026 come due between 2029 and 2031. Those years will show whether the forecast replacement wave turns up in real orders.

Oct 26, 2026

Why shared auto-injectors keep forcing rebuilt device files

Why shared auto-injectors keep forcing rebuilt device files

Vertex Knight co-founder Fubin Wu cites digitalization, personalization and large-volume delivery as trends reshaping drug delivery devices, arguing structured data can enable reuse and cut duplicated design-file work for shared auto-injectors. ISPE says no regulatory pathway exists for platform devices, and ONdrugDelivery counts 182 large-volume subcutaneous biologics, about 15% of IV and SC agents.

  • 01A device shared across drug products still triggers repeated design control work for each new combination product, and ISPE's November 2025 article says no regulatory pathway yet exists to approve a platform device.
  • 02FDA's May 2024 draft platform technology designation under section 506K is written for drug product applications, so device design files sit outside it.
  • 03Large-volume subcutaneous biologics above 2 mL numbered 182 in a January 2025 ONdrugDelivery review, about 15% of IV and SC agents; Advanced Drug Delivery Reviews reported in July 2026 that volumes up to 25 mL are now pursued.

Oct 22, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

VR Intern at NASA's Kennedy Space Center

Tanya Gupta is a VR intern at NASA's Kennedy Space Center. She is involved in leveraging VR technology to enhance aerospace engineering processes. Her work emphasizes the importance of creativity in the STEM fields.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512